Recent trials with a “High Impact” on current daily practice – A 360° journal search
Journal of Current Cardiology · 2025
DOI: 10.4103/jcc.jcc_11_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Current Cardiology, 2025. Verfasst von Suman Bhandari und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
1. Association between cigarette smoking and subclinical markers of cardiovascular harm Yao Z, Tasdighi E, Dardari ZA, Jha KK, Osuji N, Rajan T, et al. Association between cigarette smoking and subclinical markers of cardiovascular harm. J Am Coll Cardiol 2025;85:018-1034. New question: The study sought to explore the detailed relationships between smoking intensity, pack-years, and time since cessation with inflammation, thrombosis, and subclinical atherosclerosis markers of cardiovascular harm. Key findings: A total of 15.3% of participants currently smoke (mean 16.7 cigarettes/day and mean 30.0 pack-years) and 34.6% of participants formerly smoked (median 19.0 years since quitting and mean 22.4 pack-years). Participants with a history of smoking showed higher levels of all subclinical markers compared with those who have never smoked, with stronger associations observed in those currently smoke. Among participants who currently smoke, smoking intensity showed a clear dose–response relationship with all markers, except for D-dimer, specifically with incremental 1%–9% higher levels of subclinical markers per 10 cigarettes. After 20 cigarettes, the patterns appeared to plateau for blood markers, while they continued to increase for atherosclerosis markers. Among those who have ever smoked, robust dose–response relationships were observed for pack-years with all subclinical markers, with incremental 1%–9% higher levels per 10 pack-years. The dose–response effects persisted after 20 pack-years for all markers, though with a milder slope. Among participants who smoked formerly, there were substantially lower levels of biomarkers with longer time since quitting, and most markers were not different compared with those who have never smoked by 30 years, except for the coronary artery calcium score, which remained 19% higher even beyond quitting after 30 years. Clinical implications and meaning: Smoking-relevant parameters show strong and dose–response relationships across 3 domains of subclinical markers of cardiovascular harm. The sensitivity of the tested subclinical markers to small increments in cigarette exposure suggests potential value in the regulation of new and existing tobacco products. 2. Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): A randomised, open-label, multicentre trial Choi KH, Park YH, Lee JY, Jeong JO, Kim CJ, Yun KH, et al. Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): A randomised, open-label, multicentre trial. Lancet 2025;405:1252-63. New question: The optimal strategy for long-term antiplatelet maintenance for patients who underwent percutaneous coronary intervention (PCI) remains uncertain. This study aimed to compare the efficacy and safety of clopidogrel versus aspirin monotherapy in patients who completed a standard duration of dual antiplatelet therapy (DAPT) following PCI with drug-eluting stents. Key findings: Between August 10, 2020, and July 31, 2023, 5542 patients were assessed for eligibility, and 5506 were randomly assigned (2752 to clopidogrel monotherapy and 2754 to aspirin monotherapy). The median time between PCI and randomization was 17.5 months (interquartile range [IQR] 12.6–36.1 months). During a median follow-up period of 2.3 years (IQR 1.6–3.0), the primary endpoint occurred in 92 patients in the clopidogrel group and 128 patients in the aspirin group (Kaplan–Meier estimated 3-year incidence 4.4% [95% CI 3.4–5.4] vs. 6.6% [5.4–7.8]; hazard ratio [HR] 0.71 [95% CI 0.54–0.93]; P = 0.013). Death from any cause occurred in 50 patients in the clopidogrel group and 70 in the aspirin group (2.4% [1.6–3.1] vs. 4.0% [2·9–5·0] at 3 years; 0.71 [0.49–1.02]); myocardial infarction (MI) in 23 patients in the clopidogrel group and 42 in the aspirin group (1.0% [0.6–1.4] vs. 2.2% [1.4–2.9] at 3 years; 0.54 [0.33–0.90]); and stroke in 23 in the clopidogrel group and 29 in the aspirin group (1.3% [0.7–2.0] vs. 1.3% [0.8–1.7] at 3 years; 0.79 [0.46–1.36]). There was no difference in the risk of bleeding between the clopidogrel and aspirin groups (3.0% [2.0–3.9] vs. 3.0% [2.2–3.9] at 3 years; 0.97 [0.67–1.42]). Clopidogrel was not associated with a higher incidence of any adverse event compared with aspirin. Clinical implications and meaning: Among patients who were at high risk of recurrent ischemic events and who completed the standard duration of DAPT following PCI, clopidogrel monotherapy, compared with aspirin monotherapy, significantly reduced the cumulative incidence of a composite of death from any cause, MI, and stroke, without an apparent increase in the risk of bleeding.3. Early ezetimibe initiation after myocardial infarction protects against later cardiovascular outcomes in the SWEDEHEART registry Leosdottir M, Schubert J, Brandts J, Gustafsson S, Cars T, Sundström J, et al. Early ezetimibe initiation after myocardial infarction protects against later cardiovascular outcomes in the SWEDEHEART registry. J Am Coll Cardiol 2025;85:1550-64. New question: Combination lipid-lowering therapy (LLT) after MI achieves lower low-density lipoprotein cholesterol (LDL-C) levels and better cardiovascular outcomes versus statin monotherapy. As a result, global guidelines recommend lower LDL-C but, paradoxically, advise treatment through a stepwise approach. Yet the need for combination therapy is inevitable as 2.5 mm and for true CBLs. Clinical implications and meaning: Among patients treated for CBLs with provisional stenting, FKB had no significant impact on MACE but was associated with a mild reduction in the incidence of the LOCO.8. Long-term outcomes of patients requiring pacemaker implantation after transcatheter aortic valve replacement: The SwissTAVI registry Badertscher, P, Stortecky, S, Serban, T, et al. Long-Term Outcomes of Patients Requiring Pacemaker Implantation After Transcatheter Aortic Valve Replacement: The SwissTAVI Registry. J Am Coll Cardiol Intv 2025;18:1163-71. Available from: https://doi.org/10.1016/j.jcin.2025.03.028. New question: To evaluate the all-cause and cardiovascular mortality of patients undergoing PM implant after TAVR. Key findings: Among 13,360 patients enrolled (mean age 82 ± 7 years, 47% female, self-expanding valves 48%, median follow-up 889 [365–1765] days), 2028 (15%) required PM within 30 days post-TAVR. Patients requiring post-TAVR PM implantation were older (82 ± 6 vs. 81 ± 7 years), predominantly male (58% vs. 50%), and more often had atrial fibrillation (34% vs. 29%). At 1-year follow-up, these patients had higher overall (adjusted HR [aHR] 1.15, 95% CI 1.05–1.26, P = 0.002) and cardiovascular mortality (aHR 1.25, 95% CI 1.06–1.46, P = 0.006). These trends persisted at 5-year and 10-year follow-up. After multivariable adjustments, significantly higher rates of cardiovascular mortality, LVEF decline ≥10%, and NYHA III-IV at 1-year follow-up were observed (aHR 1.44, 95%CI 1.35–1.54, P < 0.001), along with higher all-cause and cardiovascular mortality rates at 5-year and 10-year follow-up in patients requiring PM implantation following TAVR compared to those not needing a PM. Clinical implications and meaning: In this large nationwide registry, patients receiving PM implantation within 30 days after TAVR had significantly higher rates of overall and cardiovascular mortality up to 10 years. 9. 5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis Forrest JK, et al. 5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis. J Am Coll Cardiol New question: This study sought to evaluate 5-year clinical and outcomes with TAVR versus in patients from the trial. Key findings: A total of patients underwent an implant = = The mean age was years years), and for of At years, the for the primary endpoint of all-cause mortality or stroke was for the TAVR group and for the group (P = The in the TAVR and groups for all-cause mortality were and (P = and for stroke were and 4.0% (P = mortality was in the TAVR group and in the group (P = mortality in the TAVR group was and in the group (P = A was performed for patients who were to follow-up or from the the of these the all-cause mortality rate at years for patients undergoing TAVR was and for was (P = Over years, the valve rate was for TAVR and for (P = A in of was observed in both treatment with mean of ± in TAVR and ± in Clinical implications and meaning: At years, patients with aortic stenosis who were treated with either TAVR or had rates of all-cause mortality or Valve and were in both Transcatheter versus surgical aortic valve replacement in The trial D, P, N, S, N, et al. Transcatheter versus surgical aortic valve replacement in The trial. J New question: with aortic stenosis have more complications when undergoing surgical valve they are in clinical The in all Aortic stenosis trial the of and of versus in Key findings: At underwent and were treated as The mean age was years, and the mean estimated surgical risk of death was of risk of the primary endpoint event rates at 1 were in the and in the group. This difference of with an 95% confidence of the noninferiority of (P < 0.001). The 95% CI of to resulted in (P = The 1-year incidence of the primary endpoint with versus with for death from any cause, versus 3.0% for stroke, and versus for Clinical implications and meaning: Among with aortic the incidence of the composite of stroke, or at 1 was lower with with and of There are no of
Zitieren
APA
Bhandari, S., & Dey, N. (2025). Recent trials with a “High Impact” on current daily practice – A 360° journal search. Journal of Current Cardiology. https://doi.org/10.4103/jcc.jcc_11_25
Vancouver
Bhandari S, Dey N. Recent trials with a “High Impact” on current daily practice – A 360° journal search. Journal of Current Cardiology. 2025. doi:10.4103/jcc.jcc_11_25
BibTeX
@article{Bhandari2025,
author = {Bhandari, Suman and Dey, Nilashish},
title = {Recent trials with a “High Impact” on current daily practice – A 360° journal search},
journal = {Journal of Current Cardiology},
year = {2025},
doi = {10.4103/jcc.jcc_11_25}
}
EUVIMED